Viking Therapeutics (VKTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $25.17, -8.04% vs the prior close of $27.37.
- Volume 7.56M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VKTX slides 8.0% to $25.17, a 52-week low. Closed at $25.17, -8.04% vs the prior close of $27.37. Day range $24.94–$27.21, opened at $27.17.
VKTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VKTX slides 8.0% to $25.17, a 52-week low
- Closed at $25.17, -8.04% vs the prior close of $27.37. Day range $24.94–$27.21, opened at $27.17.
- Volume was 7.56M shares, 1.5x its 50-day average of 5.02M.
- Price is -21.8% vs its 50-day average ($32.17) and -23.2% vs its 200-day average ($32.76).
- 52-week range $24.94–$43.15; today's close sits at 1% of that range, 41.7% below the 52-week high.
Oct 15, 2026 — VKTX jumps 7.5% to $27.37
- Closed at $27.37, +7.46% vs the prior close of $25.47. Day range $25.86–$27.51, opened at $26.10.
- Volume was 5.22M shares, 1.1x its 50-day average of 4.95M.
- Price is -15.4% vs its 50-day average ($32.33) and -16.6% vs its 200-day average ($32.81).
- 52-week range $25.28–$43.15; today's close sits at 12% of that range, 36.6% below the 52-week high.
Oct 14, 2026 — VKTX slides 4.4% to $25.47, a 52-week low, 3 down days in a row
- Closed at $25.47, -4.43% vs the prior close of $26.65. Day range $25.28–$26.89, opened at $26.50.
- Volume was 6.58M shares, 1.4x its 50-day average of 4.86M.
- Price is -21.5% vs its 50-day average ($32.46) and -22.5% vs its 200-day average ($32.85).
- 52-week range $25.28–$43.15; today's close sits at 1% of that range, 41.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — VKTX slides 6.0% to $26.65, a 6-month low
- Closed at $26.65, -5.96% vs the prior close of $28.34. Day range $26.60–$28.20, opened at $28.20.
- Volume was 5.74M shares, 1.2x its 50-day average of 4.77M.
- Price is -18.3% vs its 50-day average ($32.61) and -19.0% vs its 200-day average ($32.91).
- 52-week range $25.77–$43.15; today's close sits at 5% of that range, 38.2% below the 52-week high.
Oct 12, 2026 — VKTX dips 0.6% to $28.34
- Closed at $28.34, -0.60% vs the prior close of $28.51. Day range $27.91–$28.84, opened at $28.23.
- Volume was 2.86M shares, 0.6x its 50-day average of 4.75M.
- Price is -13.4% vs its 50-day average ($32.73) and -14.0% vs its 200-day average ($32.96).
- 52-week range $25.77–$43.15; today's close sits at 15% of that range, 34.3% below the 52-week high.
Oct 9, 2026 — VKTX rises 2.8% to $28.51
- Closed at $28.51, +2.81% vs the prior close of $27.73. Day range $27.58–$28.86, opened at $27.85.
- Volume was 4.04M shares, 0.9x its 50-day average of 4.74M.
- Price is -13.1% vs its 50-day average ($32.79) and -13.6% vs its 200-day average ($33.01).
- 52-week range $25.77–$43.15; today's close sits at 16% of that range, 33.9% below the 52-week high.
Oct 8, 2026 — VKTX dips 2.8% to $27.73, a 6-month low on 1.9x normal volume
- Closed at $27.73, -2.84% vs the prior close of $28.54. Day range $27.05–$28.49, opened at $28.37.
- Volume was 8.73M shares, 1.9x its 50-day average of 4.63M — unusually heavy trading.
- Price is -15.7% vs its 50-day average ($32.89) and -16.1% vs its 200-day average ($33.04).
- 52-week range $25.77–$43.15; today's close sits at 11% of that range, 35.7% below the 52-week high.
Oct 7, 2026 — VKTX rises 0.6% to $28.54
- Closed at $28.54, +0.56% vs the prior close of $28.38. Day range $28.12–$29.06, opened at $28.39.
- Volume was 5.40M shares, 1.2x its 50-day average of 4.57M.
- Price is -13.5% vs its 50-day average ($33.00) and -13.7% vs its 200-day average ($33.08).
- 52-week range $25.77–$43.15; today's close sits at 16% of that range, 33.9% below the 52-week high.
Oct 6, 2026 — VKTX slides 3.1% to $28.38, a 3-month low, 4 down days in a row
- Closed at $28.38, -3.07% vs the prior close of $29.28. Day range $28.17–$29.72, opened at $29.49.
- Volume was 7.11M shares, 1.6x its 50-day average of 4.46M.
- Price is -14.3% vs its 50-day average ($33.11) and -14.3% vs its 200-day average ($33.10).
- 52-week range $25.77–$43.15; today's close sits at 15% of that range, 34.2% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — VKTX dips 2.2% to $29.28, 3 down days in a row
- Closed at $29.28, -2.20% vs the prior close of $29.94. Day range $28.71–$30.18, opened at $30.14.
- Volume was 6.28M shares, 1.4x its 50-day average of 4.37M.
- Price is -11.9% vs its 50-day average ($33.24) and -11.6% vs its 200-day average ($33.13).
- 52-week range $25.77–$43.15; today's close sits at 20% of that range, 32.1% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — VKTX dips 1.9% to $29.94
- Closed at $29.94, -1.87% vs the prior close of $30.51. Day range $29.90–$31.09, opened at $30.85.
- Volume was 6.37M shares, 1.5x its 50-day average of 4.31M.
- Price is -10.2% vs its 50-day average ($33.35) and -9.7% vs its 200-day average ($33.17).
- 52-week range $25.77–$43.15; today's close sits at 24% of that range, 30.6% below the 52-week high.
VKTX latest news & SEC filings
Every SEC filing by or about VKTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Sep 25, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 25, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 24, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 23, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 23, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 30, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lian Brian sold 148,517 shares at $33.32 (≈$4.95M) on Jul 29, 2026
- Lian Brian sold 148,517 shares at $33.32 (≈$4.95M) on Jul 29, 2026
- Lian Brian sold 148,517 shares at $33.32 (≈$4.95M) on Jul 29, 2026
- Lian Brian sold 148,517 shares at $33.32 (≈$4.95M) on Jul 29, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zante Greg sold 21,217 shares at $33.47 (≈$710.13K) on Jul 29, 2026
- Zante Greg sold 21,217 shares at $33.47 (≈$710.13K) on Jul 29, 2026
- Zante Greg sold 21,217 shares at $33.47 (≈$710.13K) on Jul 29, 2026
- Zante Greg sold 21,217 shares at $33.47 (≈$710.13K) on Jul 29, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mancini Marianna sold 18,217 shares at $33.47 (≈$609.72K) on Jul 29, 2026
- Mancini Marianna sold 18,217 shares at $33.47 (≈$609.72K) on Jul 29, 2026
- Mancini Marianna sold 18,217 shares at $33.47 (≈$609.72K) on Jul 29, 2026
- Mancini Marianna sold 18,217 shares at $33.47 (≈$609.72K) on Jul 29, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 29, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$128.02M (prior year -$65.56M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.10 (prior year -$0.58) (loss widened vs Jun 30, 2025)
Things to know before you trade VKTX
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: Apr 29, 2026, Feb 11, 2026, Oct 22, 2025. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.80% (largest 35.7%). That is a volatile stock.
- Liquidity: about 10.03M shares (≈$252.52M) trade per day on average.
- 52-week position: $25.17 vs a range of $24.94–$43.15 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Greg Zante sold 21,217 shares on Jul 29, 2026.
- Latest filings: 8-K Sep 28, 2026; 8-K Sep 22, 2026; 10-Q Jul 29, 2026.
- Share count: 116.65M shares outstanding (Jul 15, 2026), +3.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VKTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 27.17 | 27.21 | 24.94 | 25.17 | 7.56M |
| Oct 15, 2026 | 26.10 | 27.51 | 25.86 | 27.37 | 5.22M |
| Oct 14, 2026 | 26.50 | 26.89 | 25.28 | 25.47 | 6.58M |
| Oct 13, 2026 | 28.20 | 28.20 | 26.60 | 26.65 | 5.74M |
| Oct 12, 2026 | 28.23 | 28.84 | 27.91 | 28.34 | 2.86M |
| Oct 9, 2026 | 27.85 | 28.86 | 27.58 | 28.51 | 4.04M |
| Oct 8, 2026 | 28.37 | 28.49 | 27.05 | 27.73 | 8.73M |
| Oct 7, 2026 | 28.39 | 29.06 | 28.12 | 28.54 | 5.40M |
| Oct 6, 2026 | 29.49 | 29.72 | 28.17 | 28.38 | 7.11M |
| Oct 5, 2026 | 30.14 | 30.18 | 28.71 | 29.28 | 6.28M |
| Oct 2, 2026 | 30.85 | 31.09 | 29.90 | 29.94 | 6.37M |
| Oct 1, 2026 | 31.92 | 32.48 | 30.43 | 30.51 | 6.83M |
| Sep 30, 2026 | 31.85 | 33.29 | 31.20 | 32.60 | 7.00M |
| Sep 29, 2026 | 33.11 | 33.65 | 31.42 | 31.81 | 8.03M |
| Sep 28, 2026 | 35.00 | 35.19 | 32.91 | 33.03 | 8.58M |
| Sep 25, 2026 | 37.80 | 39.04 | 35.10 | 35.56 | 13.58M |
| Sep 24, 2026 | 36.03 | 37.22 | 35.11 | 36.75 | 28.71M |
| Sep 23, 2026 | 41.76 | 43.10 | 37.71 | 41.65 | 15.73M |
| Sep 22, 2026 | 37.00 | 41.72 | 36.34 | 40.85 | 41.23M |
| Sep 21, 2026 | 29.57 | 30.70 | 28.41 | 30.11 | 5.09M |
About Viking Therapeutics
Viking Therapeutics (VKTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1607678.
VKTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Matthew W Foehr | Director | Jan 5, 2026 |
| Dorothy Elizabeth Kelly-Gemmell | Director | Aug 7, 2026 |
| Brian Lian | President & CEO | Jul 29, 2026 |
| Lawson Macartney | Director | Jan 5, 2026 |
| Sarah Kathryn Rouan | Director | Jan 5, 2026 |
| Charles A Jr Rowland | Director | Jan 5, 2026 |
| J Matthew Singleton | Director | Jan 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Neil William Aubuchon | Chief Commercial Officer | Mar 10, 2026 |
| Hubert C Chen | Chief Medical Officer | Jun 3, 2026 |
| Brian Lian | President & CEO | Jul 29, 2026 |
| Marianna Mancini | Chief Operating Officer | Jul 29, 2026 |
| Greg Zante | Chief Financial Officer | Jul 29, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 29, 2026 | Greg Zante | Sale | 21,217 | $33.47 |
| Jul 29, 2026 | Greg Zante | Sale | 21,217 | $33.47 |
| Jul 29, 2026 | Greg Zante | Sale | 21,217 | $33.47 |
| Jul 29, 2026 | Greg Zante | Sale | 21,217 | $33.47 |
| Jul 29, 2026 | Marianna Mancini | Sale | 18,217 | $33.47 |
| Jul 29, 2026 | Marianna Mancini | Sale | 18,217 | $33.47 |
| Jul 29, 2026 | Marianna Mancini | Sale | 18,217 | $33.47 |
| Jul 29, 2026 | Marianna Mancini | Sale | 18,217 | $33.47 |
| Jul 29, 2026 | Brian Lian | Sale | 148,517 | $33.32 |
| Jul 29, 2026 | Brian Lian | Sale | 148,517 | $33.32 |
| Jul 29, 2026 | Brian Lian | Sale | 148,517 | $33.32 |
| Jul 29, 2026 | Brian Lian | Sale | 148,517 | $33.32 |
| Mar 10, 2026 | Neil William Aubuchon | Buy | 4,475 | $33.50 |
| Mar 10, 2026 | Neil William Aubuchon | Buy | 4,475 | $33.50 |
| Mar 10, 2026 | Neil William Aubuchon | Buy | 4,475 | $33.50 |
VKTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-359.64M | -3.19 | $-278.69M |
| Dec 31, 2024 | $0 | $-109.96M | -1.01 | $-87.79M |
| Dec 31, 2023 | $0 | $-85.89M | -0.91 | $-73.38M |
| Dec 31, 2022 | $0 | $-68.87M | -0.90 | $-48.40M |
| Dec 31, 2021 | $0 | $-54.99M | -0.71 | $-47.59M |
Latest balance sheet: total assets $521.90M, total liabilities $113.58M, cash $125.75M (as of Jun 30, 2026).
VKTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $33.43 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $31.33 |
| Feb 11, 2026 | 8-K Item 2.02 (results) | $28.55 |
| Oct 22, 2025 | 8-K Item 2.02 (results) | $31.42 |
| Jul 23, 2025 | 8-K Item 2.02 (results) | $33.40 |
| Apr 23, 2025 | 8-K Item 2.02 (results) | $25.79 |
| Feb 5, 2025 | 8-K Item 2.02 (results) | $33.50 |
| Oct 23, 2024 | 8-K Item 2.02 (results) | $60.39 |
| Jul 24, 2024 | 8-K Item 2.02 (results) | — |
| Apr 24, 2024 | 8-K Item 2.02 (results) | — |
| Feb 7, 2024 | 8-K Item 2.02 (results) | — |
| Oct 25, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VKTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.